By Layal Liverpool BCG vaccine (red, lower left) infecting a human white blood cell (green)NIBSC/SCIENCE PHOTO LIBRARY The BCG (Bacillus Calmette-Guérin) tuberculosis vaccine boosts the production of immune cells, which may explain why it can protect newborn babies from dying of sepsis. Previous studies have shown that BCG vaccination can protect newborns against a broad… Read More »
Researchers at Trinity College Dublin have identified a so-called “executioner cell” that may hold the key to eventually finding a treatment to slow retinal degeneration that causes blindness in millions of people each year. A multi-disciplinary team involving experts from TCD believe they have pinpointed a potential new therapeutic target for treating retinal degeneration. It… Read More »
Print this page 30 March 2020 — AstraZeneca’s Imfinzi (durvalumab) has been approved in the US as a 1st-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) in combination with standard-of-care (SoC) chemotherapies, etoposide plus either carboplatin or cisplatin (platinum-etoposide). The approval by the Food and Drug Administration was based on positive results from… Read More »
By Layal Liverpool We don’t know why some people who have allergies lose their sense of smellRuslan Nassyrov / Alamy Stock Photo Mice have tens of thousands of chemical sensing nose cells that can cause an allergic reaction. Researchers say this discovery could help us understand how the immune system reacts to inhaled allergens and… Read More »
(Reuters) – Nearly half of lymphoma patients treated with Gilead Sciences Inc’s Yescarta were alive at least three years after a one-time infusion of the CAR-T cell therapy, according to data presented on Saturday. FILE PHOTO: A Gilead Sciences, Inc. logo is seen outside the company headquarters in Foster City, California, U.S. May 1, 2018.… Read More »
FDA Approves Oxbryta (voxelotor) for the Treatment of Sickle Cell Disease Print this page SOUTH SAN FRANCISCO, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) — Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Oxbryta™ (voxelotor) tablets for the treatment of sickle cell disease (SCD) in adults and children… Read More »